Why Australia should reschedule MDMA and psilocybin for the treatment of mental illness
Cognitive-behavioral approach to treatment of obesity yields significant results
20 May 2021Challenging the standard model of cancer
20 May 2021Why Australia should reschedule MDMA and psilocybin for the treatment of mental illness
The Therapeutic Goods Administration (TGA) is considering rescheduling psilocybin and MDMA from their current classification as Schedule 9 prohibited substances to Schedule 8 controlled substances.
